Eli Lilly and Company (LLY)
Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
Eli Lilly and Co (NYSE:LLY) shares surged 9.5% in Wednesday morning trading after the drugmaker posted fourth-quarter results that topped Wall Street expectations and issued a robust forecast for 2026, fueled by soaring demand for its weight‑loss treatments. The company reported revenue of $19.29 billion for the fourth quarter, up 43% from a year earlier and well above analysts' estimate of $18.01 billion.
3 Reasons A Pullback In Eli Lilly Stock Is Likely
Eli Lilly (LLY) is encountering challenges. Even well-established companies are not immune to corrections.
Eli Lilly (LLY) Q4 Earnings and Revenues Beat Estimates
Eli Lilly (LLY) came out with quarterly earnings of $7.54 per share, beating the Zacks Consensus Estimate of $6.99 per share. This compares to earnings of $5.32 per share a year ago.
Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand
Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, as it expects strong demand for its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro, to offset pricing pressures in the U.S., its largest market.
Jim Cramer on what is driving Eli Lilly's stock right now
'Mad Money' host Jim Cramer looks ahead to next week's market moving moments.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.27% move from the preceding trading day.
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity drugs. That includes a closely watched experimental drug called retatrutide, which has shown the highest weight loss of any treatment seen to date in a late-stage trial.
Pennsylvania Wins Bid for Eli Lilly Weight-Loss Drug Factory
The region is attempting to build on its status as a manufacturing hub with bigger investments and more tax perks for corporate investors.
Unveiling Lilly (LLY) Q4 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Eli Lilly partners with Seamless Therapeutics on gene editing treatments for hearing loss
Eli Lilly and Co (NYSE:LLY) announced that it has entered a strategic global research collaboration and licensing agreement with Seamless Therapeutics to develop and commercialize programmable recombinase-based treatments for certain hearing loss indications. The collaboration will use Seamless' proprietary recombinase platform, which enables large, precise DNA insertions independent of the cell's natural DNA repair mechanisms.
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
